Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.
Circ J. 2017 Nov 24;81(12):1758-1763. doi: 10.1253/circj.CJ-17-1103. Epub 2017 Nov 2.
From August 26th to 30th, the 2017 Annual Congress of the European Society of Cardiology (ESC 2017) was held in Barcelona, Spain. Despite the terrorism tradegy just before the ESC congress, the congress attracted many medical professionals from all over the world to discuss the recent topics in cardiovascular medicine in more than 500 sessions, including COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS Trial), CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study), and ORION (which assessed the effect of a novel siRNA inhibitor to PCSK9 on reductions in low-density lipoprotein cholesterol). Japanese cardiologists and the Japanese Circulation Society greatly contributed to the congress. This report briefly introduces some late-breaking registry results, late-breaking clinical trials, and ESC Guidelines from the ESC 2017 Congress.
从 8 月 26 日至 30 日，欧洲心脏病学会（ESC）2017 年年会在西班牙巴塞罗那举行。尽管在 ESC 大会之前发生了恐怖主义悲剧，但仍吸引了来自世界各地的许多医学专业人士参加，他们在 500 多个会议上讨论了心血管医学的最新主题，包括 COMPASS（使用抗凝策略治疗的患者心血管结果试验）、CANTOS（卡那单抗抗炎血栓形成结局研究）和 ORION（评估新型 siRNA 抑制剂对 PCSK9 的影响，以降低低密度脂蛋白胆固醇）。日本心脏病专家和日本循环学会为大会做出了巨大贡献。本报告简要介绍了 ESC 2017 年大会上的一些最新注册研究结果、最新临床试验和 ESC 指南。
